Department of Medical Sciences, Division of Rheumatology, Uppsala University, Uppsala 751 85, Sweden; Department of Internal Medicine, Division of Rheumatology, Istanbul Bilim University, Istanbul, Turkey.
Department of Rheumatology, Eskişehir Osmangazi University, Eskişehir, Turkey.
Semin Arthritis Rheum. 2020 Dec;50(6):1387-1393. doi: 10.1016/j.semarthrit.2020.02.020. Epub 2020 Mar 4.
Detailed analysis of hematological manifestations (HM) in systemic lupus erythematosus (SLE) are limited and their clinical impact on disease remain obscure. Here, we aimed to decipher factors associated with different hematological abnormalities in SLE patients and to assess their impact on disease related outcomes.
A dataset (GIPT) originating from SLE patients of six European tertiary centers was assessed. Six-monthly visits of each patient for at least 2 years were registered. The association between hematologic manifestations (HM; per ACR-1997criteria) and clinical/serologic variables, as well as the impact of HM on disease related outcomes (damage, infection and hemorrhage) were explored. Scores on the Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI2K), the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) and events for any infection and hemorrhage were recorded. Results were compared with a cross-sectional, well-characterized SLE dataset from Sweden. Descriptive statistics, the generalized estimating equations (GEE), general linear models (GLM), Cox regression models were applied.
We monitored 1425 longitudinal visits in 286 SLE patients with HM (GIPT dataset: 88% female, 95% Caucasian, 68% dsDNA positive). Thrombocytopenia (regression coefficient [95% confidence interval] 1.86[1.1-3.13]) and neurologic involvement (ACR-8) (2.1[1.10-3.89]) were associated with lymphopenia (<1000/mm); the latter was an independent predictor of organ damage accrual (1.68[1.2-2.62]). These associations were confirmed in an independent dataset of 1348 SLE patients (86% female, 93% Caucasian, 61% dsDNA positive) in Sweden.Severe lymphopenia (<500/mm) and severe thrombocytopenia (<20 K/mm) were associated with increased risk for infection (hazard ratio [95% confidence interval] 2.56[1.23-5.31]) and hemorrhage (4.38[2.10-11.1]), respectively, independent of the effect of other predictors.
Lymphopenia in SLE is independently associated with neurologic involvement and organ damage accrual, and thus, may be considered as a marker of severe/progressive disease.
对系统性红斑狼疮(SLE)患者的血液学表现(HM)进行详细分析,并探讨其对疾病的临床影响十分有限。本研究旨在解析与 SLE 患者不同血液学异常相关的因素,并评估其对疾病相关结局的影响。
评估了源自欧洲六个三级中心的 SLE 患者的数据集(GIPT)。对每位患者至少 2 年的每 6 个月的就诊情况进行了登记。通过 ACR-1997criteria 评估血液学表现(HM)与临床/血清学变量之间的关联,以及 HM 对疾病相关结局(损伤、感染和出血)的影响。记录系统性红斑狼疮疾病活动指数 2000(SLEDAI2K)、系统性红斑狼疮国际合作临床(SLICC)/美国风湿病学会(ACR)损伤指数(SDI)的评分以及任何感染和出血的事件。结果与来自瑞典的具有代表性的 SLE 数据集进行了比较。采用描述性统计、广义估计方程(GEE)、一般线性模型(GLM)、Cox 回归模型进行分析。
我们监测了 286 例有 HM 的 SLE 患者的 1425 次纵向就诊(GIPT 数据集:88%为女性,95%为白种人,68%dsDNA 阳性)。血小板减少症(回归系数[95%置信区间]1.86[1.1-3.13])和神经系统受累(ACR-8)(2.1[1.10-3.89])与淋巴细胞减少症(<1000/mm)相关;后者是器官损伤进展的独立预测因子(1.68[1.2-2.62])。在瑞典的另一项包含 1348 例 SLE 患者(86%为女性,93%为白种人,61%dsDNA 阳性)的独立数据集的研究中证实了这些关联。严重的淋巴细胞减少症(<500/mm)和严重的血小板减少症(<20K/mm)与感染(危险比[95%置信区间]2.56[1.23-5.31])和出血(4.38[2.10-11.1])的风险增加相关,且独立于其他预测因素的影响。
SLE 中的淋巴细胞减少症与神经受累和器官损伤进展相关,因此可被视为严重/进展性疾病的标志物。